Stem Cell News Texas House Bill 810
Completed Legislative Action
Spectrum: Moderate Partisan Bill (Republican 18-5)
Status: Passed on June 12 2017 – 100% progression
Action: 2017-06-12 – Effective on 9/1/17
Text:
Spectrum: Moderate Partisan Bill (Republican 18-5)
Status: Passed on June 12 2017 – 100% progression
Action: 2017-06-12 – Effective on 9/1/17
Text:
Summary Texas House Bill 810
Relating to the provision of certain investigational stem cell treatments to patients with certain severe chronic diseases or terminal illnesses and regulating the possession, use, and transfer of adult stem cells; creating a criminal offense.
Stem Cell Leads for providers
Texas House Bill 810 History
Date | Chamber | Stem Cell House Bill Action |
---|---|---|
2017-06-12 | Effective on 9/1/17 | |
2017-06-12 | Signed by the Governor | |
2017-05-30 | Sent to the Governor | |
2017-05-30 | Senate | Signed in the Senate |
2017-05-29 | House | Signed in the House |
2017-05-29 | House | Reported enrolled |
2017-05-28 | Senate | House adopts conf. comm. report-reported |
2017-05-28 | House | Record vote |
2017-05-28 | House | Statement of Leg. Intent Recorded in Journal |
2017-05-28 | House | House adopts conference committee report |
2017-05-28 | House | Senate adopts conf. comm. report-reported |
2017-05-28 | Senate | Remarks ordered printed |
2017-05-28 | Senate | Record vote |
2017-05-28 | Senate | Senate adopts conference committee report |
2017-05-28 | Senate | Co-sponsor authorized |
2017-05-27 | House | Conf. Comm. Report distributed |
2017-05-27 | Senate | Conference committee report filed |
2017-05-26 | House | Senate appoints conferees-reported |
2017-05-26 | House | Senate grants request for conf comm-reported |
2017-05-26 | Senate | Co-sponsor authorized |
2017-05-26 | Senate | Senate appoints conferees |
2017-05-26 | Senate | Senate grants request for conference comm. |
2017-05-26 | Senate | House appoints conferees-reported |
2017-05-26 | Senate | House requests conference committee-reported |
2017-05-26 | Senate | House refuses to concur-reported |
2017-05-26 | House | House appoints conferees |
2017-05-26 | House | House requests conference committee |
2017-05-26 | House | House refuses to concur in Senate amendments |
2017-05-25 | House | Senate Amendments Analysis distributed |
2017-05-25 | House | Senate Amendments distributed |
2017-05-24 | House | Senate passage as amended reported |
2017-05-24 | Senate | Record vote |
2017-05-24 | Senate | Passed |
2017-05-24 | Senate | Read 3rd time |
2017-05-24 | Senate | Record vote |
2017-05-24 | Senate | Three day rule suspended |
2017-05-24 | Senate | Vote recorded in Journal |
2017-05-24 | Senate | Passed to 3rd reading as amended |
2017-05-24 | Senate | Vote recorded in Journal |
2017-05-24 | Senate | Amended |
2017-05-24 | Senate | Amendment(s) offered |
2017-05-24 | Senate | Vote recorded in Journal |
2017-05-24 | Senate | Amended |
2017-05-24 | Senate | Amendment(s) offered |
2017-05-24 | Senate | Read 2nd time |
2017-05-24 | Senate | Rules suspended-Regular order of business |
2017-05-24 | Senate | Co-sponsor authorized |
2017-05-24 | Senate | Placed on intent calendar |
2017-05-22 | Senate | Committee report printed and distributed |
2017-05-22 | Senate | Reported favorably w/o amendments |
2017-05-22 | Senate | Considered in public hearing |
2017-05-17 | Senate | Left pending in committee |
2017-05-17 | Senate | Testimony taken in committee |
2017-05-17 | Senate | Considered in public hearing |
2017-05-17 | Senate | Scheduled for public hearing on . . . |
2017-05-17 | Senate | Posting rule suspended |
2017-05-15 | Senate | Referred to Health & Human Services |
2017-05-15 | Senate | Read first time |
2017-05-15 | Senate | Received from the House |
2017-05-12 | House | Reported engrossed |
2017-05-12 | House | Record vote |
2017-05-12 | House | Passed |
2017-05-12 | House | Read 3rd time |
2017-05-11 | House | Passed to engrossment as amended |
2017-05-11 | House | Amended |
2017-05-11 | House | Read 2nd time |
2017-05-08 | House | Placed on General State Calendar |
2017-05-05 | House | Considered in Calendars |
2017-05-04 | House | Committee report sent to Calendars |
2017-05-04 | House | Committee report distributed |
2017-05-03 | House | Comte report filed with Committee Coordinator |
2017-04-27 | House | Reported favorably as substituted |
2017-04-27 | House | Committee substitute considered in committee |
2017-04-27 | House | Considered in formal meeting |
2017-04-18 | House | Left pending in committee |
2017-04-18 | House | Testimony taken/registration(s) recorded in committee |
2017-04-18 | House | Committee substitute considered in committee |
2017-04-18 | House | Considered in public hearing |
2017-04-18 | House | Scheduled for public hearing on . . . |
2017-02-21 | House | Referred to Public Health |
2017-02-21 | House | Read first time |
2017-01-03 | House | Filed |
85R4702 SCL-F | ||
By: Parker | H.B. No. 810 |
relating to the provision of certain investigational stem cell | ||
treatments to patients with certain severe chronic diseases or | ||
terminal illnesses. | ||
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
SECTION 1. Chapter 1003, Health and Safety Code, is amended | ||
by designating Sections 1003.001, 1003.002, and 1003.003 as | ||
Subchapter A and adding a subchapter heading to read as follows: | ||
SUBCHAPTER A. GENERAL PROVISIONS | ||
SECTION 2. Chapter 1003, Health and Safety Code, is amended | ||
by adding Subchapter B to read as follows: | ||
SUBCHAPTER B. PROVISION OF INVESTIGATIONAL STEM CELL TREATMENTS TO | ||
PATIENTS WITH CERTAIN SEVERE CHRONIC DISEASES OR TERMINAL ILLNESSES | ||
Sec. 1003.051. DEFINITIONS. In this subchapter: | ||
(1) “Investigational stem cell treatment” means an | ||
adult stem cell treatment that: | ||
(A) is under investigation in a clinical trial | ||
and being administered to human participants in that trial; and | ||
(B) has not yet been approved for general use by | ||
the United States Food and Drug Administration. | ||
(2) “Severe chronic disease” means a condition, | ||
injury, or illness that: | ||
(A) may be treated; | ||
(B) is never cured or eliminated; and | ||
(C) entails significant functional impairment or | ||
severe pain. | ||
(3) “Terminal illness” means an advanced stage of a | ||
disease with an unfavorable prognosis that, without | ||
life-sustaining procedures, will soon result in death or a state of | ||
permanent unconsciousness from which recovery is unlikely. | ||
Sec. 1003.052. RULES. The executive commissioner shall | ||
adopt rules designating the medical conditions that constitute a | ||
severe chronic disease or terminal illness for purposes of this | ||
subchapter. | ||
Sec. 1003.053. PATIENT ELIGIBILITY. A patient is eligible | ||
to access and use an investigational stem cell treatment under this | ||
subchapter if: | ||
(1) the patient has a severe chronic disease or | ||
terminal illness listed in the rules adopted under Section 1003.052 | ||
and attested to by the patient’s treating physician; and | ||
(2) the patient’s physician: | ||
(A) in consultation with the patient, has | ||
considered all other treatment options currently approved by the | ||
United States Food and Drug Administration and determined that | ||
those treatment options are unavailable or unlikely to alleviate | ||
the significant impairment or severe pain associated with the | ||
severe chronic disease or terminal illness; and | ||
(B) has recommended or prescribed in writing that | ||
the patient use a specific class of investigational stem cell | ||
treatment. | ||
Sec. 1003.054. INFORMED CONSENT. (a) Before receiving an | ||
investigational stem cell treatment, an eligible patient must sign | ||
a written informed consent. | ||
(b) If the patient is a minor or lacks the mental capacity to | ||
provide informed consent, a parent, guardian, or conservator may | ||
provide informed consent on the patient’s behalf. | ||
(c) The executive commissioner by rule may adopt a form for | ||
the informed consent under this section. | ||
Sec. 1003.055. NO CAUSE OF ACTION CREATED. This subchapter | ||
does not create a private or state cause of action against a | ||
developer of an investigational stem cell treatment or against any | ||
other person or entity involved in the care of an eligible patient | ||
using the investigational stem cell treatment for any harm done to | ||
the eligible patient resulting from the investigational stem cell | ||
treatment. | ||
Sec. 1003.056. EFFECT ON HEALTH CARE COVERAGE FOR CLINICAL | ||
TRIAL ENROLLEES. This subchapter does not affect the coverage of | ||
enrollees in clinical trials under Chapter 1379, Insurance Code. | ||
Sec. 1003.057. ACTION AGAINST PHYSICIAN’S LICENSE | ||
PROHIBITED. Notwithstanding any other law, the Texas Medical Board | ||
may not revoke, fail to renew, suspend, or take any action against | ||
a physician’s license under Subchapter B, Chapter 164, Occupations | ||
Code, based solely on the physician’s recommendations to an | ||
eligible patient regarding access to or use of an investigational | ||
stem cell treatment, provided that the care provided or | ||
recommendations made to the patient meet the standard of care and | ||
the requirements of this subchapter. | ||
Sec. 1003.058. GOVERNMENTAL INTERFERENCE PROHIBITED. (a) | ||
In this section, “governmental entity” means this state or an | ||
agency or political subdivision of this state. | ||
(b) A governmental entity or an officer, employee, or agent | ||
of a governmental entity may not interfere with an eligible | ||
patient’s access to or use of a stem cell treatment authorized under | ||
this subchapter. | ||
SECTION 3. As soon as practicable after the effective date | ||
of this Act, the executive commissioner of the Health and Human | ||
Services Commission shall adopt rules necessary to implement | ||
Subchapter B, Chapter 1003, Health and Safety Code, as added by this | ||
Act. | ||
SECTION 4. This Act takes effect immediately if it receives | ||
a vote of two-thirds of all the members elected to each house, as | ||
provided by Section 39, Article III, Texas Constitution. |